Abstract
High-dose interferon (IFN)α-2b has shown benefits in the adjuvant treatment of melanoma, but relapse-free and overall survival remain poor, despite the use of chemotherapy, vaccines, and combinations of these modalities. Questions remain in relation to the relative importance of dose, route and duration of immunotherapy needed to prevent relapse and improve survival. Our understanding of STAT signaling, the role of dendritic and T cells and of circulating cytokine profiles in this benefit of IFN therapy have yet to be deployed clinically. The EORTC 18991 trial analyzed whether pegylated IFNα-2b delivered for up to 5 years could improve tolerability and efficacy of IFN. The study demonstrated an improvement in a subset of patients with microscopic disease, but not in those with gross nodal involvement. The potential role of this agent needs to be examined in relation to the long-term control of relapse. Assessment of the molecular, immunological, and antiangiogenic effects of the various forms of pegylated IFN will be critical to identification of the best future applications for these modalities.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kirkwood JM et al. (1996) Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7–17
Kirkwood JM et al. (2000) High- and low-dose interferon α-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18: 2444–2458
Kirkwood JM et al. (2001) High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB–III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19: 2370–2380
Gogas H et al. (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354: 709–718
Yurkovetsky ZR et al. (2007) Multiplex analysis of serum cytokines in melanoma patients treated with interferonα-2b. Clin Cancer Res 13: 2422–2428
Wang W et al. (2007) Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNα-2b. Clin Cancer Res 13: 1523–1531
Eggermont AMS et al. (2008) Adjuvant therapy with pegylated interferon α-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372: 117–126
Wang W et al. (2007) Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNα-2b. Clin Cancer Res 13: 1523–1531
Yurkovetsky ZR et al. (2007) Multiplex analysis of serum cytokines in melanoma patients treated with interferon α2b. Clin Cancer Res 13: 2422–2428
Balch CM et al. (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622–3634
Kirkwood JM et al. (2008) The next generation of immunotherapy for melanoma. J Clin Oncol 26: 3445–3455
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
JM Kirkwood is on the Speakers bureau and receives grant/research support from Schering-Plough. All other authors declared no competing interests.
Rights and permissions
About this article
Cite this article
Kirkwood, J., Tawbi, H., Tarhini, A. et al. Does pegylated interferon α-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?. Nat Rev Clin Oncol 6, 70–71 (2009). https://doi.org/10.1038/ncponc1297
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1297
This article is cited by
-
Prognostic significance of autoimmunity during treatment of melanoma with interferon
Seminars in Immunopathology (2011)